ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$39.77
−0.53%Sep 10, 2026, 10:30 UTC
Roivant reported strong efficacy for its pipeline drug mosliciguat in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Source:Sep 8, 2026, 10:11 UTC
Roivant Sciences announced that its experimental lung disease drug met the main goal in a mid-stage study, causing its shares to surge 21.1% in pre-market trading.
Source:Sep 7, 2026, 13:56 UTC
Roivant and its subsidiary Pulmovant announced that results from the Phase 2 PHocus study of Mosliciguat in PH-ILD will be presented at the ERS International Congress 2026 on September 8, 2026.
Aug 28, 2026, 13:46 UTC
Roivant and Priovant Therapeutics launched their newly approved rare disease drug Lisraya at a list price of $35,000 for a 30-day supply on Friday.
Source:Aug 6, 2026, 11:00 UTC
Roivant is on track to launch brepocitinib for dermatomyositis by the end of September 2026.
Aug 6, 2026, 11:00 UTC
Roivant reported financial results for the first quarter ended June 30, 2026, with consolidated cash of $3.9 billion as of that date.
Source:Aug 6, 2026, 00:00 UTC
Roivant Sciences Ltd. repurchased 7.3 million shares of its common stock for approximately $208.7 million during Q1 2026.